# FORM 4

# UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. *See* Instruction 1(b).

#### STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

pe Response	s)															
1. Name and Address of Reporting Person * Mann Brenda				2. Issuer Name and Ticker or Trading Symbol EYEGATE PHARMACEUTICALS INC [EYEG]								5. Relationship of Reporting Person(s) to Issuer (Check all applicable)  Director X Officer (give title below) Other (specify below)				
(Last) (First) (Middle) C/O EYEGATE PHARMACEUTICALS, INC., 271 WAVERLY OAKS ROAD, SUITE 108				3. Date of Earliest Transaction (Month/Day/Year) 09/02/2020									VP of Re	search & De	evelopment	
(Street) WALTHAM, MA 02452				4. If Amendment, Date Original Filed(Month/Day/Year)							6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting PersonForm filed by More than One Reporting Person					
	(State)	(Zip)	Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned													
1.Title of Security (Instr. 3)  2. Transaction Date (Month/Day/Yo			any		Code (Instr		(A) or Disposed of (D) (Instr. 3, 4 and 5)		D) E	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)			Form: Direct (D) or Indirect	7. Nature of Indirect Beneficial Ownership (Instr. 4)		
					Coo	de	V	Amoun	-		ce				(Instr. 4)	
Stock		09/02/2020			F	1)		97	D	~	4 1	17,656			D	
Report on a s	separate line fo	Table II -	Derivative Sec	curiti	ies Acq	quire	Pers cont the f	ons what in the constant in th	no resp n this f splays	orm a a cur	are r rrent cially	not requ lly valid	ired to res	pond unle	ss	1474 (9-02)
2	3 Transaction		371			s, opt						e and	8 Price of	0 Number	of 10	11. Natur
	n Date (Month/Day/	Execution Da any	ate, if Transaction Code				and Expiration Date (Month/Day/Year)		A U S (1	Amount of Underlying Securities (Instr. 3 and 4)		Derivative Security	Derivative Securities Beneficially Owned Following Reported	Owners Form o Derivat Securit Direct ( or Indir	hip of Indired Beneficia Ownersh (Instr. 4) D)	
			Code	V	(A)					ion T	Γitle	or Number of				
	AM, MA (  Conversion or Exercise Price of Derivative	(Street)  AM, MA 02452  (State)  ecurity  Stock  Report on a separate line for Exercise Price of Derivative	d Address of Reporting Person* enda  (First) (Middle) EGATE PHARMACEUTICALS, I WAVERLY OAKS ROAD, SUITE  (Street)  AM, MA 02452 (State) (Zip)  ecurity 2. Transaction Date (Month/Day/Year)  Stock 09/02/2020  Report on a separate line for each class of security  Table II -  Conversion or Exercise Price of Derivative (Month/Day/Year)  3A. Deemed Execution Date (Month/Day/Year) (Month/Day/Year) (Month/Day/Year)	and Address of Reporting Person* enda  2. Issuer Nation (Middle) EYEGATI [EYEG] 3. Date of Ea (09/02/2020)  Street)  4. If Amendry  AM, MA 02452 (State)  2. Transaction Date (Month/Day/Year)  EYEGATI [EYEG]  3. Date of Ea (09/02/2020)  4. If Amendry  AM, MA 02452 (Month/Day/Year)  2. Transaction Date (Month/Day/Year)  EXECUTION (Middle)  Stock  4. If Amendry  2. Transaction Date (Month/Day/Year)  AND EXECUTION (Month/Day/Year)  Table II - Derivative Securities benefician  Table II - Derivative Securities benefician  Table II - Derivative Securities benefician  AND Date (Month/Day/Year)  (Month/Day/Year)  AND Deemed Execution Date (E.g., puts, call any (Month/Day/Year)  (Month/Day/Year)	and Address of Reporting Person*  enda  2. Issuer Name a EYEGATE PERFECT PERFECT PERFECT PERFECT PERFECT PHARMACEUTICALS, 1 WAVERLY OAKS ROAD, SUITE  (Street)  4. If Amendment, AM, MA 02452  2. Transaction Date (Month/Day/Year)  2. Transaction Date (Month/Day/Year)  2. Transaction Date (Month/Day/Year)  2. Table II - Derivative Securities beneficially on Execution Date, if any (Month/Day/Year)  2. Table II - Derivative Securities beneficially on Exercise (Month/Day/Year)  3. Transaction Date (Month/Day/Year)  2. Table II - Derivative Securities beneficially on Exercise (Month/Day/Year)  (Month/Day/Year)	d Address of Reporting Person* enda  2. Issuer Name and Tic EYEGATE PHARM [EYEG]  3. Date of Earliest Trans: 09/02/2020  3. Date of Earliest Trans: 09/02/2020  4. If Amendment, Date Code (Month/Day/Year)  (Street)  4. If Amendment, Date Code (Instr. any (Month/Day/Year))  2. Transaction Date (Month/Day/Year)  2. Transaction Date (Month/Day/Year)  2. Transaction Date (Execution Date, if any (Month/Day/Year))  3. Transaction Date (E.g., puts, calls, warrants: 00/02/2020  Table II - Derivative Securities Accession of Execution Date, if any (Month/Day/Year)  2. Table II - Derivative Securities Deneficially owned described in the properties of Date (Month/Day/Year)  3. Transaction Date (E.g., puts, calls, warrants: 00/06/06/06/06/06/06/06/06/06/06/06/06/0	d Address of Reporting Person* enda  2. Issuer Name and Ticker of EYEGATE PHARMAC [EYEG]  3. Date of Earliest Transaction (99/02/2020)  4. If Amendment, Date Origin (Month/Day/Year)  (Street)  4. If Amendment, Date Origin (Month/Day/Year)  2. Transaction Date (Month/Day/Year)  2. Transaction Date (Month/Day/Year)  2. Transaction Date (Instr. 8)  Code  Table II - Derivative Securities Acquire (e.g., puts, calls, warrants, op of Derivative Security  3. Date of Earliest Transaction (99/02/2020)  4. If Amendment, Date Origin (Month/Day/Year)  2. Table II - Derivative Securities beneficially owned direct (e.g., puts, calls, warrants, op of Derivative Securities (Month/Day/Year)  3. Transaction Date (Instr. 8)  Code  (Instr. 8)  5. Number (Gode)  (Instr. 8)  Derivative Securities Acquire (e.g., puts, calls, warrants, op of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	Code	d Address of Reporting Person enda    Code   V   Amount	2. Issuer Name and Ticker or Trading Symbol EYEGATE PHARMACEUTICALS INCEXTED	2. Issuer Name and Ticker or Trading Symbol EYEGATE PHARMACEUTICALS INC [EYEG]  3. Date of Earliest Transaction (Month/Day/Year)  4. If Amendment, Date Original Filed(Month/Day/Year)  5. Table I - Non-Derivative Securities Acquired (Instr. 8)  6. Code	and Address of Reporting Person and and Ticker or Trading Symbol EYEGATE PHARMACEUTICALS INC [EYEG]  Comparison (Pirst) (Middle) Comparison (Middle) Code (Instr. 8) Code (Misstr. 8) Code (Mistr. 8) Code (Misstr. 8) Code (Misstr. 8) Code (Mistr. 8)	2. Issuer Name and Ticker or Trading Symbol EYEGATE PHARMACEUTICALS INC [EYEG]   3. Date of Earliest Transaction (Month/Day/Year)   5. Relation Direct (EYEG)   6. Individual (Month/Day/Year)   6. Individual (Month/Day/Year)   7. Transaction (	2. Issuer Name and Ticker or Trading Symbol EYEGATE PHARMACEUTICALS INC [EYEG]  3. Date of Earliest Transaction (Month/Day/Year)  9/02/2020  4. If Amendment, Date Original Filed(Month/Day/Year)  9/02/2020  4. If Amendment, Date Original Filed(Month/Day/Year)  1. If Amendment, Date Original Filed(Month/Day/Year)  1. If Amendment, Date Original Filed(Month/Day/Year)  1. If Amendment, Date Original Filed(Month/Day/Year)  2. Transaction Date (Month/Day/Year)  2. Transaction Date (Month/Day/Year)  2. Transaction Date (Month/Day/Year)  2. Transaction Date (Month/Day/Year)  3. Transaction (Instr. 8) (Instr. 3, 4 and 5)  4. If Amendment, Date Original Filed(Month/Day/Year)  5. Amount of Date Original Filed(Month/Day/Year)  6. Individual or Joint/Cate Original Filed(Month/Day/Year)  8. Amount of Code (Instr. 3, 4 and 5)  8. Relationship of Rep  1. If Amendment, Date Original Filed(Month/Day/Year)  8. Amount of Date Original Filed(Month/Day/Year)  9. If Amount of Date Original Filed(Month/Day/Year)  9. If Amount of Date Original Filed(Month/Day/Year)  9. If Amount of Date Original Filed(Month/Day/Year)  1. If Amendment, Date Original Filed(Month/Day/Year)  1. If Amendment, Date Original Filed(Month/Day/Year)  1. If Amount of Date Original Filed(Month/Day/Year)  1. If Amount of Da	2. Issuer Name and Ticker or Trading Symbol EYEGATE PHARMACEUTICALS INC [EYEG] 3. Date of Earliest Transaction (Month/Day/Year) 0/9/02/2020 4. If Amendment, Date Original Filed(Month/Day/Year) 0/9/02/2020 5. Relationship of Reporting Person Notice (Garce (A) or Disposed of Chole (Instr. 3) and 4) 1. Stock 09/02/2020 5. Relationship of Reporting Person Notice (Garce) Note (Month/Day/Year) Notice (Garce) Note (Month/Day/Year) Note (Month/Day/Y	2. Issuer Name and Ticker or Trading Symbol EYEGATE PHARMACEUTICALS INC [EYFG]  (Size) (Size) (Modalla) (SGATE PHARMACEUTICALS, I WAVERLY OAKS ROAD, SUITE  (Size) 4. If Amendment, Date Original Filed(Momb/Day/Year) (Size) 5. Relationship of Reporting Person(s) to Issue (Citeck all applicable) (Citeck all applicable) (Size) VP of Research & Development  Table 1 - Non-Derivative Securities Acquired (A) or Disposed of Original Filed(Momb/Day/Year) (Month/Day/Year) (Month/Day/Year) (Month/Day/Year) (Month/Day/Year) (Month/Day/Year) (Month/Day/Year) (Month/Day/Year) (Size) 5. Relationship of Reporting Person(s) to Issue (Citeck all applicable) (Month/Day/Year) (A) Original Filed(Momb/Day/Year) (Month/Day/Year) (Month/

### **Reporting Owners**

	Relationships					
Reporting Owner Name / Address		10% Owner	Officer	Other		
Mann Brenda C/O EYEGATE PHARMACEUTICALS, INC. 271 WAVERLY OAKS ROAD, SUITE 108 WALTHAM, MA 02452			VP of Research & Development			

## **Signatures**

/s/ Sarah Romano, Attorney-in-Fact*	09/03/2020

**Signature of Reporting Person	Date

#### **Explanation of Responses:**

- \* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) Sale of shares to cover taxes due on restricted stock that vested on 09/01/2020.
  - The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$3.93 to \$3.94, inclusive. The reporting
- (2) person hereby undertakes to provide to EyeGate Pharmaceuticals, Inc., any security holder of EyeGate Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.